1. European Parliament and Council of the European Union (2012) Directive 2001/83/EC on the community code relating to medicinal products for human use, as amended.
http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf
. Accessed 24 Aug 2016
2. Chan BK, Abedon ST, Loc-Carillo C (2013) Phage cocktails and the future of phage therapy. Future Microbiol 8:769–783. doi:
10.2217/fmb.13.47
3. Huys I, Pirnay JP, Lavigne R, Jennes S, De Vos D, Casteels M, Verbeken G (2013) Paving a regulatory pathway for phage therapy. EMBO Rep 14:951–954. doi:
10.1038/embor.2013.163
4. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R (2011) The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm Res 28:934–937. doi:
10.1007/s11095-010-0313-5
5. Chan BK, Abedon ST (2012) Phage therapy pharmacology phage cocktails. Adv Appl Microbiol 78:1–23. doi:
10.1016/B978-0-12-394805-2.00001-4